mitotane has been researched along with ACTH Syndrome, Ectopic in 7 studies
Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.
ACTH Syndrome, Ectopic: Symptom complex due to ACTH production by non-pituitary neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitotane is a drug which is concentrated largely in adipose tissue and the adrenal glands." | 5.27 | Primary hypogonadism associated with o,p' DDD (mitotane) therapy. ( Sparagana, M, 1987) |
| "ACTH-dependent Cushing's syndrome is a heterogeneous disorder requiring a multidisciplinary and individualized approach to patient management." | 2.44 | Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. ( Bertagna, X; Bertherat, J; Biller, BM; Boscaro, M; Buchfelder, M; Colao, A; Grossman, AB; Hermus, AR; Hofland, LJ; Klibanski, A; Lacroix, A; Lindsay, JR; Melmed, S; Newell-Price, J; Nieman, LK; Petersenn, S; Sonino, N; Stalla, GK; Stewart, PM; Swearingen, B; Vance, ML; Wass, JA, 2008) |
| "Mitotane is a drug which is concentrated largely in adipose tissue and the adrenal glands." | 1.27 | Primary hypogonadism associated with o,p' DDD (mitotane) therapy. ( Sparagana, M, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Salle, L | 1 |
| Mas, R | 1 |
| Teissier-Clément, MP | 1 |
| Donadille, B | 1 |
| Groussin, L | 1 |
| Waintrop, C | 1 |
| Abbas, H | 1 |
| Tenenbaum, F | 1 |
| Dugué, MA | 1 |
| Coste, J | 1 |
| Bertagna, X | 2 |
| Bertherat, J | 2 |
| Biller, BM | 1 |
| Grossman, AB | 1 |
| Stewart, PM | 1 |
| Melmed, S | 1 |
| Buchfelder, M | 1 |
| Colao, A | 1 |
| Hermus, AR | 1 |
| Hofland, LJ | 1 |
| Klibanski, A | 1 |
| Lacroix, A | 1 |
| Lindsay, JR | 1 |
| Newell-Price, J | 1 |
| Nieman, LK | 1 |
| Petersenn, S | 1 |
| Sonino, N | 1 |
| Stalla, GK | 1 |
| Swearingen, B | 1 |
| Vance, ML | 1 |
| Wass, JA | 1 |
| Boscaro, M | 1 |
| Aron, DC | 1 |
| Findling, JW | 1 |
| Fitzgerald, PA | 1 |
| Forsham, PH | 1 |
| Wilson, CB | 1 |
| Tyrrell, JB | 1 |
| Kuhn, JM | 1 |
| Proeschel, MF | 1 |
| Seurin, DJ | 1 |
| Bertagna, XY | 1 |
| Luton, JP | 1 |
| Girard, FL | 1 |
| Sparagana, M | 2 |
| Ackerman, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine[NCT02160730] | Phase 2 | 4 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to NIH grant ended.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of participants that achieved a urinary free cortisol level above the upper limit of the normal range but reduced by ≥50% from baseline at week 4. (NCT02160730)
Timeframe: Baseline, Week 4
| Intervention | Participants (Count of Participants) |
|---|---|
| R-roscovitine | 2 |
A visible change in tumor size as determined by the investigator after reviewing MRI reports between baseline and 4 weeks of treatment. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| R-roscovitine | 0 |
"To evaluate the efficacy of R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks on normalizing 24 hour urinary free cortisol (24 h UFC) levels in CD patients. Normalizing is defined as having urine free cortisol levels within the normal range for that lab value." (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| R-roscovitine | 0 |
The number of participants that experience an adverse event between baseline and study end likely related to study drug as a measure of safety and tolerability. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| R-roscovitine | 2 |
Change in typical Cushing's syndrome clinical signs and symptoms defined by mean weight at baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | lbs (Mean) | |
|---|---|---|
| Baseline | 4 Weeks | |
| R-roscovitine | 217 | 217.4 |
Mean diastolic blood pressure between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline | 4 Weeks | |
| R-roscovitine | 76.5 | 71 |
HbA1c levels are measured at baseline and at study end, these are averaged across all subjects. (NCT02160730)
Timeframe: Baseline, 4 Weeks
| Intervention | Percentage (Mean) | |
|---|---|---|
| Baseline | Study End-4 weeks | |
| R-roscovitine | 6.9 | 7 |
Mean change in systolic blood pressure between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline | 4 weeks | |
| R-roscovitine | 150.3 | 128.3 |
Mean serum cortisol values at baseline and 4 weeks (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline | 4 Weeks | |
| R-roscovitine | 25.6 | 27.1 |
Mean change between baseline and week 4 of fasting blood glucose levels. (NCT02160730)
Timeframe: Baseline, 4 Weeks
| Intervention | g/dL (Mean) | |
|---|---|---|
| Baseline | 4 weeks | |
| R-roscovitine | 121.4 | 104.3 |
Mean change in Plasma ACTH between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Baseline | 4 weeks | |
| R-roscovitine | 79.3 | 79.9 |
2 reviews available for mitotane and ACTH Syndrome, Ectopic
| Article | Year |
|---|---|
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.
Topics: ACTH Syndrome, Ectopic; Adrenal Insufficiency; Adrenalectomy; Adrenocorticotropic Hormone; Cushing S | 2008 |
Cushing's syndrome: problems in management.
Topics: ACTH Syndrome, Ectopic; Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Adrenocorticotropic Hormone | 1982 |
5 other studies available for mitotane and ACTH Syndrome, Ectopic
| Article | Year |
|---|---|
Ectopic adrenocortical carcinoma of the ovary: An unexpected outcome.
Topics: ACTH Syndrome, Ectopic; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Ag | 2020 |
Management of Cushing's syndrome due to ectopic adrenocorticotropin secretion with 1,ortho-1, para'-dichloro-diphenyl-dichloro-ethane: findings in 23 patients from a single center.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Adult; Aged; Aged, 80 and over; Cushing Syndrom | 2010 |
Comparative assessment of ACTH and lipotropin plasma levels in the diagnosis and follow-up of patients with Cushing's syndrome: a study of 210 cases.
Topics: ACTH Syndrome, Ectopic; Adenoma; Adolescent; Adrenal Gland Neoplasms; Adrenalectomy; Adrenocorticotr | 1989 |
Positive iodine-131 6 beta-iodomethyl-19-norcholesterol (NP-59) adrenal images can precede return of adrenocortical function after o,p' DDD treatment.
Topics: 19-Iodocholesterol; ACTH Syndrome, Ectopic; Adrenal Glands; Adult; Cholesterol; Humans; Iodine Radio | 1988 |
Primary hypogonadism associated with o,p' DDD (mitotane) therapy.
Topics: ACTH Syndrome, Ectopic; Adult; Erectile Dysfunction; Gonadotropins; Humans; Hypogonadism; Luteinizin | 1987 |